Index RUT
P/E -
EPS (ttm) -0.87
Insider Own 5.05%
Shs Outstand 150.29M
Perf Week -9.18%
Market Cap 416.41M
Forward P/E -
EPS next Y -0.06
Insider Trans 4.26%
Shs Float 142.74M
Perf Month 2.59%
Income -110.56M
PEG -
EPS next Q -0.07
Inst Own 71.21%
Short Float 17.81%
Perf Quarter 65.87%
Sales 127.04M
P/S 3.28
EPS this Y 73.33%
Inst Trans 7.14%
Short Ratio 8.27
Perf Half Y 179.54%
Book/sh -0.23
P/B -
EPS next Y 70.31%
ROA -46.70%
Short Interest 25.43M
Perf Year 72.05%
Cash/sh 0.53
P/C 5.18
EPS next 5Y 47.50%
ROE -2408.88%
52W Range 0.50 - 3.22
Perf YTD 62.94%
Dividend Est. -
P/FCF -
EPS past 5Y 20.01%
ROI -77.54%
52W High -13.98%
Beta 1.68
Dividend TTM -
Quick Ratio 1.84
Sales past 5Y 17.85%
Gross Margin 48.75%
52W Low 454.00%
ATR (14) 0.22
Dividend Ex-Date -
Current Ratio 2.37
EPS Y/Y TTM 49.36%
Oper. Margin -87.07%
RSI (14) 50.85
Volatility 6.65% 8.28%
Employees 126
Debt/Eq -
Sales Y/Y TTM 17.99%
Profit Margin -87.02%
Recom 1.00
Target Price 7.00
Option/Short Yes / Yes
LT Debt/Eq -
EPS Q/Q 57.19%
Payout -
Rel Volume 0.36
Prev Close 2.74
Sales Surprise 9.63%
EPS Surprise 54.49%
Sales Q/Q 14.00%
Earnings Mar 12 AMC
Avg Volume 3.08M
Price 2.77
SMA20 0.08%
SMA50 6.24%
SMA200 69.60%
Trades
Volume 1,104,457
Change 1.09%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-13-24 Reiterated
Needham
Buy
$4 → $5
May-27-20 Initiated
Guggenheim
Buy
$24
Feb-20-20 Reiterated
Needham
Buy
$50 → $48
Jan-16-19 Reiterated
Needham
Buy
$66 → $64
Apr-05-18 Initiated
Evercore ISI
Outperform
$56
Mar-19-18 Reiterated
Mizuho
Buy
$28 → $35
Mar-01-18 Reiterated
Needham
Buy
$28 → $30
Jan-03-18 Initiated
Leerink Partners
Outperform
$22
Sep-27-17 Initiated
Northland Capital
Outperform
$40
Feb-27-17 Initiated
Needham
Buy
$28
Oct-26-16 Initiated
Aegis Capital
Buy
Sep-06-16 Resumed
Lake Street
Buy
$45
May-03-16 Initiated
Cantor Fitzgerald
Buy
Dec-10-15 Initiated
Lake Street
Buy
$45
Sep-23-15 Reiterated
Leerink Partners
Outperform
$38 → $57
Sep-02-15 Initiated
BofA/Merrill
Buy
$46
Aug-03-15 Reiterated
Brean Capital
Buy
$40 → $45
Jun-30-15 Reiterated
JMP Securities
Mkt Outperform
$25 → $33
Jun-19-15 Reiterated
Leerink Partners
Outperform
$26 → $38
Aug-07-14 Initiated
Noble Financial
Buy
$18
Show Previous Ratings
Mar-28-24 04:05PM
Mar-13-24 09:19AM
07:04AM
(Thomson Reuters StreetEvents)
Mar-12-24 06:00PM
05:33PM
04:34PM
Loading…
04:34PM
(Associated Press Finance)
04:05PM
Mar-07-24 09:15AM
Feb-28-24 08:00AM
Feb-23-24 11:56AM
Feb-06-24 12:00PM
Jan-25-24 06:44AM
Jan-24-24 01:47PM
Jan-23-24 08:00PM
Jan-15-24 04:51PM
09:55AM
Loading…
09:55AM
Jan-07-24 05:00PM
Dec-10-23 12:23PM
(Associated Press Finance)
Dec-06-23 11:55AM
Nov-28-23 07:33PM
Nov-15-23 10:17AM
08:51AM
08:46AM
(Thomson Reuters StreetEvents)
Nov-14-23 06:00PM
04:17PM
(Associated Press Finance)
04:05PM
Nov-07-23 04:05PM
Aug-24-23 09:29AM
Aug-15-23 01:30PM
12:48PM
09:47AM
Loading…
09:47AM
(Thomson Reuters StreetEvents)
Aug-14-23 04:29PM
(Associated Press Finance) -6.79%
04:05PM
Aug-07-23 04:05PM
10:50AM
Jul-26-23 01:30PM
Jul-24-23 09:02AM
09:00AM
Jun-23-23 04:05PM
Jun-12-23 09:00AM
May-11-23 05:15PM
04:12PM
04:01PM
May-05-23 12:28PM
Apr-20-23 11:45AM
09:00AM
Apr-17-23 04:05PM
Apr-06-23 03:42PM
02:01PM
Apr-03-23 09:00AM
Mar-27-23 07:12AM
Mar-24-23 06:43AM
(Thomson Reuters StreetEvents) -7.75%
Mar-23-23 09:28PM
05:35PM
04:05PM
Mar-13-23 09:00AM
Mar-10-23 04:05PM
Mar-06-23 09:00AM
Feb-27-23 04:30PM
Feb-22-23 09:00AM
Jan-30-23 05:54AM
Jan-09-23 08:30AM
Dec-29-22 09:45AM
09:00AM
Dec-28-22 12:32PM
Dec-20-22 03:41PM
Nov-21-22 04:05PM
Nov-15-22 10:14PM
Nov-10-22 05:44AM
Nov-09-22 01:15PM
Nov-08-22 06:25PM
04:05PM
Nov-04-22 11:48AM
Nov-01-22 04:05PM
Sep-26-22 09:45AM
Sep-23-22 09:19AM
07:30AM
Sep-19-22 06:42AM
Sep-16-22 02:49PM
Sep-12-22 07:37AM
Aug-23-22 12:00PM
Aug-15-22 09:55AM
Aug-09-22 02:10PM
09:15AM
08:01AM
08:00AM
Aug-02-22 04:05PM
Jul-21-22 06:32AM
Jul-18-22 06:00PM
Jun-30-22 08:41AM
08:30AM
Jun-14-22 08:30AM
May-26-22 04:05PM
May-16-22 04:05PM
May-09-22 06:45PM
04:05PM
May-03-22 04:05PM
Apr-05-22 04:05PM
Mar-28-22 03:14PM
Mar-25-22 08:30AM
Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Forbes William P EVP, Chief Development Officer Nov 17 '23 Buy 1.09 25,000 27,250 79,000 Nov 21 12:19 PM Collard Craig A Chief Executive Officer Nov 16 '23 Buy 0.92 150,000 137,970 186,496 Nov 17 12:37 PM Duarte Ira EVP, Chief Financial Officer Nov 16 '23 Buy 0.89 85,000 75,599 85,000 Nov 17 12:36 PM Forbes William P EVP, Chief Development Officer Nov 16 '23 Buy 0.94 50,000 46,995 54,000 Nov 20 10:07 AM Morgan Adam Director Jul 21 '23 Buy 1.37 2,486,744 3,406,839 6,986,744 Jul 25 04:22 PM
Index -
P/E -
EPS (ttm) -1.38
Insider Own 16.30%
Shs Outstand 225.41M
Perf Week -10.61%
Market Cap 266.18M
Forward P/E -
EPS next Y -0.69
Insider Trans 0.51%
Shs Float 188.82M
Perf Month -13.24%
Income -179.82M
PEG -
EPS next Q -0.18
Inst Own 79.44%
Short Float 5.87%
Perf Quarter 34.12%
Sales 0.00M
P/S -
EPS this Y 36.87%
Inst Trans 11.72%
Short Ratio 10.18
Perf Half Y 49.03%
Book/sh 0.28
P/B 4.24
EPS next Y 6.90%
ROA -61.54%
Short Interest 11.09M
Perf Year -6.35%
Cash/sh 1.31
P/C 0.90
EPS next 5Y 5.20%
ROE -480.50%
52W Range 0.45 - 1.88
Perf YTD 29.32%
Dividend Est. -
P/FCF -
EPS past 5Y 11.99%
ROI -69.08%
52W High -37.23%
Beta 1.70
Dividend TTM -
Quick Ratio 5.94
Sales past 5Y 0.00%
Gross Margin -
52W Low 160.77%
ATR (14) 0.11
Dividend Ex-Date -
Current Ratio 5.94
EPS Y/Y TTM 49.48%
Oper. Margin 0.00%
RSI (14) 42.05
Volatility 6.67% 8.46%
Employees 135
Debt/Eq 3.38
Sales Y/Y TTM -
Profit Margin -
Recom 1.80
Target Price 5.97
Option/Short Yes / Yes
LT Debt/Eq 3.15
EPS Q/Q 63.89%
Payout -
Rel Volume 0.98
Prev Close 1.17
Sales Surprise -
EPS Surprise -0.82%
Sales Q/Q -
Earnings Mar 05 BMO
Avg Volume 1.09M
Price 1.18
SMA20 -14.18%
SMA50 4.50%
SMA200 16.12%
Trades
Volume 1,068,341
Change 0.85%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-27-23 Downgrade
UBS
Buy → Neutral
$8 → $1.25
Mar-07-23 Downgrade
Raymond James
Outperform → Mkt Perform
Mar-01-23 Initiated
Guggenheim
Neutral
Dec-07-22 Downgrade
SMBC Nikko
Outperform → Neutral
$3
Dec-07-22 Downgrade
JP Morgan
Neutral → Underweight
Dec-07-22 Downgrade
Barclays
Overweight → Equal Weight
$18 → $2
Oct-20-22 Initiated
Goldman
Buy
$22
Sep-21-22 Initiated
JP Morgan
Neutral
$17
Sep-19-22 Initiated
Wedbush
Outperform
$24
Apr-18-22 Initiated
Raymond James
Outperform
$19
Apr-06-22 Initiated
UBS
Buy
$19
Jan-10-22 Upgrade
SMBC Nikko
Neutral → Outperform
$24
Nov-09-21 Resumed
Cantor Fitzgerald
Overweight
$20
Sep-21-21 Resumed
Piper Sandler
Overweight
$26
Jun-29-20 Initiated
H.C. Wainwright
Buy
$31
Apr-22-20 Initiated
Piper Sandler
Overweight
$30
Feb-27-20 Initiated
Barclays
Overweight
$21
Dec-03-19 Resumed
BofA/Merrill
Buy
Oct-30-19 Initiated
Berenberg
Buy
$31
Mar-05-19 Initiated
SVB Leerink
Outperform
$30
Show Previous Ratings
Mar-13-24 07:07AM
Mar-12-24 07:31AM
Mar-07-24 09:55AM
Mar-05-24 10:52PM
07:55AM
07:40AM
Loading…
07:40AM
(Associated Press Finance)
07:31AM
Feb-27-24 03:30AM
Jan-31-24 02:23PM
Jan-22-24 10:53AM
Jan-08-24 04:01PM
Dec-13-23 04:01PM
Dec-05-23 04:01PM
07:01AM
Nov-29-23 07:01AM
08:11AM
Loading…
Nov-09-23 08:11AM
07:41AM
(Associated Press Finance)
07:31AM
Oct-23-23 10:08AM
Oct-03-23 04:08PM
Sep-07-23 07:44AM
Aug-28-23 08:20AM
Aug-08-23 04:41PM
(Associated Press Finance) -5.43%
04:01PM
Jul-24-23 04:16PM
Jul-20-23 07:56AM
Jun-23-23 06:24AM
(Zacks Small Cap Research)
May-18-23 07:05AM
May-13-23 08:15AM
May-09-23 04:13PM
04:01PM
Loading…
04:01PM
Apr-04-23 12:38PM
Mar-17-23 07:46AM
07:31AM
Mar-07-23 03:37PM
Mar-03-23 11:40AM
Feb-01-23 04:25PM
Jan-04-23 12:00PM
09:35AM
Dec-26-22 09:41AM
Dec-06-22 01:19PM
10:00AM
08:19AM
07:15AM
Nov-17-22 02:37PM
Nov-08-22 12:00PM
Nov-03-22 04:01PM
Oct-24-22 08:30AM
Aug-29-22 08:11AM
Aug-09-22 08:01AM
Jul-21-22 06:21PM
Jul-20-22 11:33AM
Jul-19-22 12:00PM
09:46AM
Jul-18-22 09:55AM
Jul-13-22 07:15AM
Jun-09-22 08:30AM
May-26-22 09:55AM
May-23-22 09:55AM
May-10-22 04:01PM
May-06-22 12:20PM
Apr-25-22 07:29AM
Mar-03-22 04:01PM
Feb-28-22 07:01AM
Jan-02-22 08:47AM
Nov-08-21 04:01PM
Nov-02-21 04:01PM
Oct-11-21 08:36AM
Oct-07-21 04:01PM
Oct-03-21 10:45AM
Sep-21-21 08:31AM
Aug-09-21 04:01PM
Aug-02-21 04:01PM
Jul-21-21 05:16AM
Jul-17-21 05:47AM
Jul-07-21 07:01AM
Jun-21-21 04:01PM
Jun-14-21 04:01PM
May-06-21 07:31AM
Apr-20-21 07:50AM
Apr-16-21 07:55AM
Feb-25-21 07:31AM
Feb-19-21 08:01AM
Feb-04-21 07:05AM
Jan-18-21 03:05AM
Dec-19-20 03:54PM
Dec-11-20 05:00PM
Dec-07-20 07:03AM
Nov-16-20 07:01AM
Nov-10-20 04:01PM
02:30PM
08:00AM
Nov-06-20 07:07AM
07:03AM
Oct-13-20 03:02PM
07:04AM
Oct-12-20 08:07AM
Oct-09-20 08:01AM
Sep-30-20 08:38AM
Sep-10-20 07:07AM
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi in 2015 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hasnain Faheem President & CEO Mar 27 '24 Sale 1.16 23,172 26,773 120,293 Mar 28 06:01 PM Giraudo Bryan COO/CFO Mar 27 '24 Sale 1.16 6,430 7,431 92,737 Mar 28 06:05 PM Christian Waage EVP, Tech Ops and Admin Mar 27 '24 Sale 1.16 6,430 7,430 585,934 Mar 28 06:16 PM Peterson Caryn EVP, Regulatory Affairs Mar 18 '24 Sale 1.33 4,018 5,343 49,833 Mar 19 06:50 PM Aranda Richard Chief Medical Officer Mar 18 '24 Sale 1.33 4,018 5,342 198,799 Mar 19 06:50 PM Milligan Sandra Director Nov 15 '23 Buy 0.79 32,000 25,213 32,000 Nov 17 04:01 PM Giraudo Bryan COO/CFO Nov 13 '23 Buy 0.56 200,000 112,880 380,010 Nov 14 06:24 PM Aranda Richard Chief Medical Officer Jun 22 '23 Sale 1.29 1,814 2,340 197,574 Jun 26 04:01 PM Giraudo Bryan COO/CFO Apr 04 '23 Buy 1.02 55,000 56,094 125,990 Apr 05 04:26 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite